Evidence map›Paper›PMID 32559474›Full record

Trial reportThe lancet. Diabetes & endocrinology2020

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.

David Z I Cherney, Claire C J Dekkers, Sean J Barbour, Daniel Cattran, Abdul Halim Abdul Gafor, Peter J Greasley, Gozewijn D Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N Reich and 5 more

Erratum issued 2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT05565976. Cited by 156 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 12 pooled it
23.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05565976 phase2 / phase3unknown status

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Ran2020Enrolled270Registered outcomes3Posted comparisons0ConditionsDementia, Vascular, Metabolic Syndrome, Mild Cognitive Impairment, Stroke, IschemicArmsAntidiabetic, Dapagliflozin 10mg Tab, Platelet Antiaggregant, Statins (Cardiovascular Agents)
PMID 29573529PMID 34813630PMID 33894597PMID 33282811PMID 33030307PMID 32854852PMID 32352644PMID 32317958PMID 32178931PMID 32144994PMID 32115470PMID 31535829other papers from this trial
Open the trial in the graph
NCT06890143 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2025 to 2027Enrolled44ConditionsPediatric Hereditary Kidney DiseasesArmsDapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 12 syntheses or guidelines pooled it, 264 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Trial
  20. Trial

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 5 countries.

David Z I CherneyDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.
Claire C J DekkersDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Sean J BarbourDivision of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Daniel CattranDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.
Abdul Halim Abdul GaforDepartment of Medicine, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
Peter J GreasleyEarly Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Gozewijn D LavermanDepartment of Internal Medicine, ZGT Hospital, Almelo and Hengelo, Netherlands.
Soo Kun LimDivision of Nephrology, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Gian Luca Di TannaThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Heather N ReichDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada.
Marc G VervloetDepartment of Nephrology and Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, Amsterdam, Netherlands.
Muh Geot WongThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.
Ron T GansevoortDepartment of Nephrology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands. Electronic address: h.j.lambers.heerspink@umcg.nl.
DIAMOND investigators
University of Toronto · CAUniversity of Groningen · NLAmsterdam University Medical Centers · NLAstraZeneca (Sweden) · SERoyal North Shore Hospital · AUUniversity Kebangsaan Malaysia Medical Centre · MYUniversity Medical Center Groningen · NLUniversity of British Columbia · CAUniversity of Malaya · MYUNSW Sydney · AUZiekenhuis Groep Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by improvements in glycaemic control alone. Therefore, we aimed to examine the kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease without diabetes.

methodsDIAMOND was a randomised, double-blind, placebo-controlled crossover trial done at six hospitals in Canada, Malaysia, and the Netherlands. Eligible participants were adult patients (aged 18-75 years) with chronic kidney disease, without a diagnosis of diabetes, with a 24-h urinary protein excretion greater than 500 mg and less than or equal to 3500 mg and an estimated glomerular filtration rate (eGFR) of at least 25 mL/min per 1·73 m

findingsBetween Nov 22, 2017, and April 5, 2019, 58 patients were screened, of whom 53 (mean age 51 years [SD 13]; 32% women) were randomly assigned (27 received dapagliflozin then placebo and 26 received placebo then dapagliflozin). One patient discontinued during the first treatment period. All patients were included in the analysis. Mean baseline mGFR was 58·3 mL/min per 1·73 m

interpretation6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes, but did induce an acute and reversible decline in mGFR and a reduction in bodyweight. Long-term clinical trials are underway to determine whether SGLT2 inhibitors can safely reduce the rate of major clinical kidney outcomes in patients with chronic kidney disease with and without diabetes.

fundingAstraZeneca.

Indexed as

AdolescentAdultAgedBenzhydryl CompoundsBiomarkersCanadaCross-Over StudiesDouble-Blind MethodFemaleFollow-Up StudiesGlomerular Filtration RateGlucosidesHumansIncidenceMaleMiddle AgedBenzhydryl CompoundsBiomarkersdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32559474
OpenAlexW3035468154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.